Patent ID: 11866742
Assignee: DENALI THERAPEUTICS INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 20:
21. A method of treating Hunter syndrome in a subject in need thereof, comprising administering to the subject a protein comprising:
a. a fusion polypeptide comprising a first Fc polypeptide linked to an iduronate 2-sulfatase (IDS) amino acid sequence, wherein the IDS amino acid sequence comprises a sequence having at least 90% identity to SEQ ID NO: 92, and wherein the IDS amino acid sequence is linked to the N-terminus of the first Fc polypeptide; and
b. a second Fc polypeptide comprising a sequence having at least 90% identity to SEQ ID NO: 151 and having the following eight residues at respective positions with reference to SEQ ID NO: 151:
i. Tyr at position 154;
ii. Thr at position 156;
iii. Glu at position 157;
iv. Trp at position 158;
v. Thr at position 183;
vi. Glu at position 185;
vii. Glu at position 186; and
viii. Phe at position 191.